Our group works on protection of humans and crops from pathogens. We do this by studying natural defences of plants, and the biology of the pathogens themselves.
Our research aims to understand the link between what immune cells ‘eat’ in our tissues and how this is connected to their normal biology and inflammatory diseases such as high blood pressure and diabetes.
Our group specialises in CD8+ T cell biology and antigen processing and presentation, particularly in relation to the development of cross-protective immune responses to the influenza virus.
Our group develops new therapeutic strategies for cancer treatment. We examine the mechanism of action of available anticancer drugs and work to restrict the killing properties to cancerous cell types.
Our group studies AAA+ proteases, responsible for general and regulated protein turn over in bacteria and in some organelles of eukaryotes.
Our group use a combination of biochemistry, cell biology, structural biology and medicinal chemistry approaches to understand the precise molecular mechanisms that control apoptosis.
Our group uses single domain antibodies that have been developed from sharks to identify novel therapeutics against a number of chronic diseases.
Our group uses an integrated systems biology approach to understand extracellular communication in the context of the tumour microenvironment and uterine development.
Our group examines apoptotic regulation in normal cells, cancerous cells and virally-infected cells. We use this knowledge to explore better and safer therapies for cancer and viral diseases.
Our group studies the molecular mechanisms underlying Gram-negative bacterial infections to develop antibacterial drugs that are not susceptible to existing resistance mechanisms.
Our group uses a combination of biochemistry, molecular and cell biology to investigate neurodegenerative diseases such as Alzheimer's, Prion and Parkinson's diseases.
Our group specialises in cancer cachexia, a complication of cancer that is responsible for around 25% of cancer deaths.
Our group studies the molecular basis of tumour progression and inflammatory disease to develop novel anti-cancer and anti-inflammatory drugs.
Our group is interested in how cell asymmetry and tissue organisation can regulate cancer initiation, progression and metastasis
Our group examines how viruses hijack cellular defence systems to ensure their own proliferation and survival.
Our group examines the molecular mechanisms underlying cell fate decisions dictated by the processes of apoptosis and autophagy.
Our group characterises the macromolecular complexes in the nucleus to understand their roles in gene regulation and DNA damage repair pathway.
Our group explores the role of extracellular matrix components (soluble secreted proteins and extracellular vesicles) in cancer and intercellular communication.
Our group studies the various aspects of skeletal muscle biochemistry in health and disease, using exercise and disease models in humans, as well as animal models.
Our group uses proof-of-concept to identify pathological and molecular mechanisms of disease. We also evaluate candidate MS drugs.
Perugini - Rational inhibitor design targeting drug-resistant bacteria, noxious weeds, and common age-related diseases
Our group studies the structure, function, regulation and inhibition of essential oligomeric enzymes such as dihydrodipicolinate synthase (DHDPS), from the lysine biosynthesis pathway of bacteria.
Our group studies the machinery that control how dying cells can disassemble into smaller pieces, and the importance of cell disassembly in disease settings, to identify new drugs to control this process.
Our group researches the molecular basis of apoptosis regulation during heart failure, sepsis and in chemo resistance.
Our group uses self-assembling biomolecules as building blocks for nanomaterials with a range of biomedical and technological applications.
Our group uses the vinegar fly, Drosophila, to model cancer with the vision of understanding how regulators of cell shape (polarity) and the cell skeleton (actin cytoskeleton) impact on cell signalling and cancer development.
Our group utilizes an integrated proteomic/genomic strategy to understand the role of the extracellular environment in cancer progression.
Our group focuses on the development and characterisation of novel classes of antibiotics and herbicides to minimise the emergence of resistance.
Our group studies the function of mitochondrial proteins involved in the biogenesis and maintenance of mitochondria at the molecular level.
Our group researches enzymes, called proteases, which operate at the interface between a host, such as a human being and microbes that cause disease.